Meeting Banner
Abstract #1760

Dynamic Contrast-Enhanced MR and Proton MR Spectroscopic Imaging in Localizing Prostate Cancer

Futterer J, Scheenen T, Heijmink S, Witjes J, Hulsbergen-van de Kaa C, Heerschap A, Barentsz J

The performance of localizing prostate cancer (PCa) throughout the whole prostate of PCa patients with T2-weighted MR imaging, dynamic contrast-enhanced MR imaging (DCE-MRI) and quantitative three-dimensional proton MR spectroscopic imaging (MRSI) was prospectively determined using whole mount section histopathology as the reference standard. Two readers evaluated 34 PCa patients and calculated the localization performance, ROI based (14 in every prostate) receiver operating characteristics (ROC) and kappa statistics, concluding that the localization performance in PCa patients of T2 weighted MR imaging improves significantly by using either DCE-MRI or MRSI.